Life sciences company Revvity (NYSE:RVTY) beat Wall Street’s revenue expectations in Q2 CY2025, with sales up 4.1% year on year to $720.3 million. The company expects the full year’s revenue to be ...
Revvity (NYSE:RVTY) has had a great run on the share market with its stock up by a significant 10% over the last three months. But the company's key financial indicators appear to be differing across ...
Revvity faces multiple headwinds including declining biotech funding, regulatory uncertainty, and reduced academic research budgets. Despite challenges, Revvity's Q1 results beat expectations and the ...
Revvity (NYSE:RVTY) will release its quarterly earnings report on Monday, 2025-04-28. Here's a brief overview for investors ahead of the announcement. Analysts anticipate Revvity to report an earnings ...
In the last three months, 8 analysts have published ratings on Revvity (NYSE:RVTY), offering a diverse range of perspectives from bullish to bearish. Summarizing their recent assessments, the table ...
Revvity (NYSE:RVTY) underwent analysis by 5 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish. The table below summarizes their recent ratings, showcasing the ...
Waltham-based biomanufacturing company Revvity is closing its Boston facility and laying off dozens of employees as a result. Revvity filed a public Worker Adjustment and Retraining Act Notification ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results